Dupixent's Ninth Life: The Drug That Won't Stop Collecting FDA Approvals

But the secondary results told an even more compelling story. Nasal congestion improved by 81% in the Dupixent group versus 11% for placebo at week 52. That's not a marginal difference; it's a different planet.

Nasal polyps shrank significantly with Dupixent compared to placebo. And the number that probably matters most to patients: the risk of needing oral steroids or another surgery dropped by 92%. In concrete terms, only 0 to 3% of Dupixent patients needed those interventions, compared to 7 to 31% on placebo.

Some patients even started regaining their sense of smell within two weeks. For people who haven't properly tasted food in years, that's not a data point. That's a life change.

The Swiss Army Knife of Biologics

AFRS is now Dupixent's ninth FDA-approved indication since its debut in 2017. Nine. In less than a decade.

The full roster reads like a type 2 inflammation greatest hits album: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, COPD, bullous pemphigoid, and now AFRS.

How does one drug treat so many different conditions? Dupixent is a monoclonal antibody that blocks two key inflammatory signals called IL-4 and IL-13. Think of those signals as the conductors of a chaotic orchestra. They drive the specific flavor of inflammation (called type 2) that underlies all nine of these diseases. Block the conductors, and the whole orchestra quiets down.

What makes this mechanistically interesting is that Dupixent isn't an immunosuppressant. It doesn't broadly dampen your immune system the way steroids do. It's more like a targeted mute button for one specific section of the immune response. That's why its safety profile has stayed relatively clean across indications: injection-site reactions, some eosinophilia (a temporary bump in certain white blood cells), occasional insomnia, and conjunctivitis are the usual suspects.

A Small Trial, a Big Question

Let's address the elephant in the room. The pivotal trial enrolled just 62 patients. That's tiny by pharmaceutical standards, where late-stage trials routinely run into the thousands.

But context matters. AFRS is uncommon, and the FDA granted this approval under priority review, recognizing the serious unmet need. When there's literally no approved drug for a condition and your trial shows a 92% reduction in the need for surgery or steroids, 62 patients can be enough to make the case.

The results were also remarkably consistent. The 50% vs. 10% split in sinus opacification held steady at both the 24-week and 52-week marks. Every secondary endpoint moved in the same direction, by large margins. When a small trial produces that kind of internal consistency, it's hard to chalk it up to noise.

Still, larger real-world studies will be important. AFRS patient populations vary by geography, ethnicity, and severity. Black patients, for instance, face 2.29 times higher odds of severe AFRS. Confirming that Dupixent works broadly across these populations will matter.

What This Means for Sanofi and Regeneron

Every new indication is another revenue stream for a drug that is already one of the best-selling biologics globally. The AFRS market isn't massive on its own; we're talking about a subset of chronic sinusitis patients. But that's the beauty of Dupixent's strategy. Each approval is incremental, and they add up.

Sanofi and Regeneron aren't done, either. Phase 3 trials are ongoing for chronic pruritus of unknown origin and lichen simplex chronicus, among others. A supplemental application to expand the chronic spontaneous urticaria indication to children ages 2 to 11 has a decision expected by April 2026.

The AFRS approval also strengthens Dupixent's position in the sino-nasal space specifically. It already had the nod for chronic rhinosinusitis with nasal polyps. Adding AFRS covers a related but distinct patient population that was previously left out of clinical trials because it was considered too different.

The Bigger Picture

For decades, AFRS patients lived in a frustrating loop: surgery, recurrence, more surgery. The only drugs available were borrowed from other conditions, used off-label, with limited evidence. Now there's a treatment backed by controlled trial data that doesn't just manage symptoms but fundamentally reduces the need for surgical intervention.

Dupixent didn't just get its ninth approval. It solved a problem that the medical community had been shrugging at for 30 years. And for the patients who've been stuck in that surgical revolving door, a subcutaneous injection every two to four weeks probably sounds like a pretty good deal.

The drug that blocks two tiny inflammatory signals keeps finding new fires to put out. At this rate, the question isn't whether Dupixent will hit a tenth indication. It's how soon.